Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eva Havrdova

Showing results (71-80 of 124) with videos related to

Pageof 13
Sort By:
The New England Journal of Medicine|March 3, 2006
A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosisChris H Polman, Paul W O'Connor, Eva Havrdova, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|January 29, 2014
Apolipoproteins are associated with new MRI lesions and deep grey matter atrophy in clinically isolated syndromesRichard W Browne, Bianca Weinstock-Guttman, Dana Horakova, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|October 6, 2018
Infection risk with alemtuzumab decreases over time: pooled analysis of 6-year data from the CAMMS223, CARE-MS I, and CARE-MS II studies and the CAMMS03409 extension studySibyl Wray, Eva Havrdova, David R Snydman, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|April 19, 2013
Lipid profiles are associated with lesion formation over 24 months in interferon-β treated patients following the first demyelinating eventBianca Weinstock-Guttman, Robert Zivadinov, Dana Horakova, et al.
Journal of Neurology|April 26, 2007
Neutralising antibodies to interferon beta in multiple sclerosis : expert panel reportHans-P Hartung, Chris Polman, Antonio Bertolotto, et al.
JAMA Neurology|March 27, 2013
Interferon beta use and disability prevention in relapsing-remitting multiple sclerosisBenjamin M Greenberg, Laura Balcer, Peter A Calabresi, et al.
Multiple Sclerosis and Related Disorders|May 30, 2018
Reply to: Comment on Y.D. Fragoso et al.: "Lymphocyte count in peripheral blood is not associated with the level of clinical response to treatment with fingolimod" [Mult. Scler. Relat. Disord. (2017)]Yara Dadalti Fragoso, Tim Spelman, Cavit Boz, et al.
Multiple Sclerosis and Related Disorders|November 29, 2017
Lymphocyte count in peripheral blood is not associated with the level of clinical response to treatment with fingolimodYara Dadalti Fragoso, Tim Spelman, Cavit Boz, et al.
Lancet (London, England)|October 31, 2008
Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb studyLudwig Kappos, Ralf Gold, David H Miller, et al.
The Journal of Steroid Biochemistry and Molecular Biology|June 21, 2014
Serum lipoprotein composition and vitamin D metabolite levels in clinically isolated syndromes: Results from a multi-center studyRichard W Browne, Bianca Weinstock-Guttman, Robert Zivadinov, et al.
Pageof 13

Showing results (71-80 of 124) with videos related to

Sort By:
Pageof 13
The New England Journal of Medicine|March 3, 2006
A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosisChris H Polman, Paul W O'Connor, Eva Havrdova, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|January 29, 2014
Apolipoproteins are associated with new MRI lesions and deep grey matter atrophy in clinically isolated syndromesRichard W Browne, Bianca Weinstock-Guttman, Dana Horakova, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|October 6, 2018
Infection risk with alemtuzumab decreases over time: pooled analysis of 6-year data from the CAMMS223, CARE-MS I, and CARE-MS II studies and the CAMMS03409 extension studySibyl Wray, Eva Havrdova, David R Snydman, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|April 19, 2013
Lipid profiles are associated with lesion formation over 24 months in interferon-β treated patients following the first demyelinating eventBianca Weinstock-Guttman, Robert Zivadinov, Dana Horakova, et al.
Journal of Neurology|April 26, 2007
Neutralising antibodies to interferon beta in multiple sclerosis : expert panel reportHans-P Hartung, Chris Polman, Antonio Bertolotto, et al.
JAMA Neurology|March 27, 2013
Interferon beta use and disability prevention in relapsing-remitting multiple sclerosisBenjamin M Greenberg, Laura Balcer, Peter A Calabresi, et al.
Multiple Sclerosis and Related Disorders|May 30, 2018
Reply to: Comment on Y.D. Fragoso et al.: "Lymphocyte count in peripheral blood is not associated with the level of clinical response to treatment with fingolimod" [Mult. Scler. Relat. Disord. (2017)]Yara Dadalti Fragoso, Tim Spelman, Cavit Boz, et al.
Multiple Sclerosis and Related Disorders|November 29, 2017
Lymphocyte count in peripheral blood is not associated with the level of clinical response to treatment with fingolimodYara Dadalti Fragoso, Tim Spelman, Cavit Boz, et al.
Lancet (London, England)|October 31, 2008
Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb studyLudwig Kappos, Ralf Gold, David H Miller, et al.
The Journal of Steroid Biochemistry and Molecular Biology|June 21, 2014
Serum lipoprotein composition and vitamin D metabolite levels in clinically isolated syndromes: Results from a multi-center studyRichard W Browne, Bianca Weinstock-Guttman, Robert Zivadinov, et al.
Pageof 13